NewsMukka Proteins Board Meeting Scheduled on May 15, 2026 to Approve Q4FY26 Results and Consider NCD IssuancesMukka Proteins Board Meeting Scheduled on May 15, 2026 to Approve Q4FY26 Results and Consider NCD Issuances
Mukka Proteins Limited has scheduled a board meeting for May 15, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider two NCD issuance proposals — one for up to Rs. 25 Cr and another for up to Rs. 50 Cr — both on a private placement basis via the Electronic Bidding Platform. The trading window for designated persons has been closed from April 1, 2026, until 48 hours post the results declaration, in line with SEBI insider trading regulations.
*this image is generated using AI for illustrative purposes only.
Mukka Proteins Limited has notified the stock exchanges of a forthcoming board meeting, scheduled for Friday, May 15, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 12, 2026, was filed by Company Secretary & Compliance Officer Mehaboobsab Mahamadgous Chalyal (Membership No.: A67502).
Key Agenda Items
The board meeting has been convened to consider and approve several significant matters. The following table summarises the key agenda items:
| Agenda Item: | Details |
|---|---|
| Financial Results: | Audited standalone and consolidated results for the quarter and year ended March 31, 2026 |
| NCD Issuance – I: | Raising of funds up to Rs. 25 Cr via non-convertible debentures on private placement basis through EBP |
| NCD Issuance – II: | Raising of funds up to Rs. 50 Cr via non-convertible debentures on private placement basis in one or more tranches/series through EBP over a period of time |
Fund-Raising Proposals
The board will deliberate on two distinct proposals for raising funds through the issuance of non-convertible debentures (NCDs) on a private placement basis via the Electronic Bidding Platform (EBP). The first proposal involves issuance of NCDs up to Rs. 25 Cr (Rupees Twenty-Five Crores only), while the second proposal pertains to issuance of NCDs up to Rs. 50 Cr (Rupees Fifty Crores only), to be issued in one or more tranches or series over a period of time.
Trading Window Closure
In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the company has been closed. The closure is effective from Wednesday, April 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for designated persons and their immediate relatives, as defined under the applicable code of conduct.
Filing Details
The intimation was formally submitted to both the National Stock Exchange of India Limited and BSE Limited on May 12, 2026, and was digitally signed by the Company Secretary & Compliance Officer on the same date.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.16% | -2.69% | +6.38% | -8.38% | -23.98% | -43.57% |
How will Mukka Proteins deploy the combined Rs. 75 Cr raised through NCDs, and which business segments or expansion plans are likely to benefit most?
What impact could the audited FY2026 financial results have on investor sentiment and the company's stock performance given current market conditions in the marine proteins sector?
How might the two-tranche NCD structure of Rs. 50 Cr affect Mukka Proteins' debt-to-equity ratio and overall credit profile going forward?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
